HomeCompareETTX vs NOBL

ETTX vs NOBL: Dividend Comparison 2026

ETTX yields 91.32% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETTX wins by $2.69M in total portfolio value
10 years
ETTX
ETTX
● Live price
91.32%
Share price
$2.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.71M
Annual income
$860,660.59
Full ETTX calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — ETTX vs NOBL

📍 ETTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETTXNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETTX + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETTX pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETTX
Annual income on $10K today (after 15% tax)
$7,762.56/yr
After 10yr DRIP, annual income (after tax)
$731,561.50/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, ETTX beats the other by $731,352.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETTX + NOBL for your $10,000?

ETTX: 50%NOBL: 50%
100% NOBL50/50100% ETTX
Portfolio after 10yr
$1.37M
Annual income
$430,453.39/yr
Blended yield
31.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ETTX right now

ETTX
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETTX buys
0
NOBL buys
0
No recent congressional trades found for ETTX or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETTXNOBL
Forward yield91.32%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$2.71M$22.8K
Annual income after 10y$860,660.59$246.19
Total dividends collected$2.40M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ETTX vs NOBL ($10,000, DRIP)

YearETTX PortfolioETTX Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$19,832$9,132.42$10,914$214.34+$8.9KETTX
2$38,148$16,926.92$11,897$218.63+$26.3KETTX
3$71,247$30,428.85$12,952$222.72+$58.3KETTX
4$129,347$53,112.88$14,086$226.62+$115.3KETTX
5$228,518$90,117.05$15,302$230.33+$213.2KETTX
6$393,309$148,794.86$16,607$233.85+$376.7KETTX
7$660,182$239,341.26$18,007$237.18+$642.2KETTX
8$1,081,855$375,459.71$19,508$240.35+$1.06METTX
9$1,732,607$575,022.24$21,116$243.35+$1.71METTX
10$2,714,550$860,660.59$22,841$246.19+$2.69METTX

ETTX vs NOBL: Complete Analysis 2026

ETTXStock

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Full ETTX Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this ETTX vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETTX vs SCHDETTX vs JEPIETTX vs OETTX vs KOETTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.